Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Gene targeting and localized delivery of anti-neoplastic agents More
A non-invasive development of a test for the diagnosis and monitoring of endometriosis. More
In addition to anti-tumor activity, these compounds have been shown to be potent irreversible inhibitors of P-glycoprotein, a member of the ABC transporter protein family that has a major role in conferring multi-drug resistance. More
Researchers at the University of Edinburgh, led by Professor Peter Sadler, have developed a novel series of platinum prodrugs, which can be activated by light (photoactivated). More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
Oligodeoxyribonucleotides containing multiple O6-benzylguanine residues may be more effective chemotherapy adjuvants than O6-benzylguanine More
Unique proangiogenic biomarkers isolated from ovarian endothelial cells More
The technology describes the humanization of a murine anti-carcinoma antibody CC49 which has been shown to react with Tumor Associated Glycoprotein 72 (TAG-72), an antigen which is expressed on human breast, ovarian, colorectal, and other carcinomas. More
Novel Diagnostic and Therapeutic Marker - ovarian and endometrial cancers More
Your selection
Browse By
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us